Optimized anti-tuberculosis duration for drug-susceptible pulmonary tuberculosis-diabetes mellitus comorbidities: study protocol for a multicenter randomized controlled trial

被引：0
|
作者：
Peize Zhang [1 ]
Huaifang Shi [2 ]
Yongping Xie [3 ]
Jiemei Liang [3 ]
Qiumeng Hu [4 ]
Liang Fu [1 ]
Yuxiang Wang [5 ]
Jie Tan [1 ]
Senlin Zhan [1 ]
Hongjuan Qin [1 ]
Guanghui Xu [1 ]
Guofang Deng [1 ]
机构：
[1] Third People’s Hospital of Shenzhen,Department of Pulmonary Medicine and Tuberculosis
[2] Shenzhen Clinical Research Center for Tuberculosis,School of Public Health
[3] Shenzhen University Medical School,undefined
[4] Shenzhen University,undefined
[5] Jiangmen Institute of Tuberculosis Prevention and Control,undefined
[6] Shenzhen University Medical School,undefined
[7] Shenzhen University,undefined
来源：
BMC Pulmonary Medicine | / 24卷 / 1期
关键词：
Drug-susceptible pulmonary tuberculosis (PTB); Type 2 diabetes(DM); Treatment duration; Unfavorable outcome; Treatment success;
D O I：
10.1186/s12890-024-03271-8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 47 条
  • [41] Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
    Jesse Ross
    Rubeshan Perumal
    Allison Wolf
    Mbali Zulu
    Kevin Guzman
    Boitumelo Seepamore
    Karl Reis
    Hlengiwe Nyilana
    Senzo Hlathi
    Radhamoney Narasimmulu
    Ying Kuen K. Cheung
    K. Rivet Amico
    Gerald Friedland
    Amrita Daftary
    Jennifer R. Zelnick
    Kogieleum Naidoo
    Max R. O’Donnell
    Trials, 24
  • [42] Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
    Nakwon Kwak
    Doosoo Jeon
    Youngmok Park
    Young Ae Kang
    Kyung Jong Kim
    Young Ran Kim
    Byoung Soo Kwon
    Yong-Soo Kwon
    Hyung-Jun Kim
    Jae Ho Lee
    Ji Yeon Lee
    Jung-Kyu Lee
    Jeongha Mok
    Minkyoung Cheon
    Jiwon Park
    Seokyung Hahn
    Jae-Joon Yim
    Trials, 23
  • [43] Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
    Kwak, Nakwon
    Jeon, Doosoo
    Park, Youngmok
    Kang, Young Ae
    Kim, Kyung Jong
    Kim, Young Ran
    Kwon, Byoung Soo
    Kwon, Yong-Soo
    Kim, Hyung-Jun
    Lee, Jae Ho
    Lee, Ji Yeon
    Lee, Jung-Kyu
    Mok, Jeongha
    Cheon, Minkyoung
    Park, Jiwon
    Hahn, Seokyung
    Yim, Jae-Joon
    TRIALS, 2022, 23 (01)
  • [44] DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial-DRKS00004550
    Kenngott, Hannes G.
    Clemens, Gabriella
    Gondan, Matthias
    Senft, Jonas
    Diener, Markus K.
    Rudofsky, Gottfried
    Nawroth, Peter P.
    Buechler, Markus W.
    Fischer, Lars
    Mueller-Stich, Beat P.
    TRIALS, 2013, 14
  • [45] DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial - DRKS00004550
    Hannes G Kenngott
    Gabriella Clemens
    Matthias Gondan
    Jonas Senft
    Markus K Diener
    Gottfried Rudofsky
    Peter P Nawroth
    Markus W Büchler
    Lars Fischer
    Beat P Müller-Stich
    Trials, 14
  • [46] Efficacy and safety of high-dose intramuscular vitamin D2 injection in type 2 diabetes mellitus with distal symmetric polyneuropathy combined with vitamin D insufficiency: study protocol for a multicenter, randomized, double-blinded, and placebo-controlled trial
    Chen, Tao
    Xing, Xiaoyan
    Huang, Lihua
    Tu, Mei
    Lai, Xiaoli
    Wen, Shidi
    Cai, Jin
    Lin, Shenglong
    Zheng, Youping
    Lin, Yuehui
    Xu, Lijuan
    Qiu, Yuwen
    Qiu, Lumin
    Xu, Yuebo
    Wu, Peiwen
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [47] INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial
    Naidoo, Anushka
    Dooley, Kelly E.
    Naidoo, Kogieleum
    Padayatchi, Nesri
    Yende-Zuma, Nonhlanhla
    Perumal, Rubeshan
    Dorse, Gillian
    Boodhram, Resha
    Osuala, Emmanuella Chinonso
    BMJ OPEN, 2022, 12 (11):
12345